Iovance Biotherapeutics Provides Cervical Cancer Program
SAN CARLOS, Calif., July 02, 2019 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology corporation growing novel most cancers based on tumor-infiltrating lymphocyte (TIL) generation, these days provided an replace on the regulatory direction for LN-145 in advanced cervical cancer. Based on…









